Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057498 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Nebulized RNS60 to Treat Asthma.
A Phase 1 study, sponsored by Revalesio Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01057498 is a Phase 1 study that has completed, run by Revalesio Corporation. The registered enrollment target is 36 participants.
The verdict
NCT01057498, a Phase 1 study, has completed, sponsored by Revalesio Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration. Second, to determine whether nebulized RNS60 is safe in human subjects with mild-to-moderate asthma over a 4-week period.
Interventions
- DRUG RNS60
- DRUG RNS60 - single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057498
The ClinicalTrials.gov registry entry for NCT01057498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revalesio Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RNS60 is the first listed.
NCT01057498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057498 about?
NCT01057498 is a clinical study titled "Safety Study of Nebulized RNS60 to Treat Asthma.". The purpose of this study is two-fold. First, to determine whether nebulized RNS60 is safe in healthy human subjects and in subjects with mild asthma, in a single-dose administration. Second, to determine whether nebulized RNS60 is safe in human subjects with mild-to-moderate asthma over a 4-week pe...
What is the current status of trial NCT01057498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01057498?
The interventions under investigation include: RNS60 (DRUG), RNS60 - single dose (DRUG).
Who is sponsoring clinical trial NCT01057498?
This trial is sponsored by Revalesio Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.